skip to Main Content

Guidance® UTI From Pathnostics Wins 2023 MedTech Breakthrough Award

IRVINE, Calif., – May 3, 2023Pathnostics, a leading precision diagnostic testing and development company, today announced that Guidance® UTI has been selected as the “Best New Technology Solution for Urology” award winner in the 7th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology market.

Guidance® UTI is Pathnostics’ advanced diagnostic testing for the rapid identification and precise treatment of complicated, recurrent, and persistent UTIs and for elevated risk patients. Guidance® UTI provides more informed treatment decisions in less than a day from samples received at the lab.

The solution is able to detect known uropathogens along with antibiotic resistance genes and incorporates a unique technology-Pooled Antibiotic Susceptibility Testing (P-ASTTM) – which provides personalized antibiotic sensitivity and resistance information and better addresses polymicrobial infections where bacterial interactions can impact antibiotic resistance.

In contrast to a standard urine culture which can take 3-5 days and often yields a substantial number of false-negative results, Guidance® UTI can identify the specific uropathogens even when multiple organisms are present.

Additionally, Guidance® UTI also identifies individual treatment options that could address polymicrobial infections quickly and provide more advanced information in cases where there are known challenges with traditional methods of treatment.

“We are delighted to be recognized with this award from MedTech Breakthrough. UTIs place a substantial burden on individual health and healthcare resources, and with the increasing rate of antibiotic resistance and UTI recurrence, it’s important that these infections be diagnosed and treated early and effectively,” said David Pauluzzi, CEO and Vice Chairman of Pathnostics. “Faster and more accurate results reduce the need for empiric therapy and support antibiotic stewardship. There are a total of 38 million UTI patient cases each year in the U.S. Guidance® UTI is designed to help the subset of 13 million complicated or recurrent cases – patients who are difficult to treat and often cycle through different antibiotic treatments.”

The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories, including Telehealth, Clinical Administration, Patient Engagement, Electronic Health Records (EHR), Virtual Care, Medical Devices, Medical Data and many more. This year’s program attracted more than 4,000 nominations from over 17 different countries throughout the world.

“While for some people, infections are easily identified and cleared with treatment from a health care provider, for some people UTIs are an ongoing problem that deeply impacts their quality of life. For these patients, or those in an elevated risk population, it’s important to identify the root of the infection quickly and begin treatment as soon as possible before the infection progresses,” said James Johnson, managing director, MedTech Breakthrough. “Pathnostics’ Guidance® UTI is a one-of-a-kind solution that addresses this complex health challenge. The breakthrough solution can help doctors select the best treatment for each individual patient, getting patients on the right treatment plan sooner. Getting the right prescription, the first time, helps reduce UTI-related emergency room visits and hospitalizations. Congratulations on being our pick for ‘Best New Technology Solution for Urology.’”

Real-world evidence from a Medicare database showed that Guidance® UTI testing is associated with reductions in critical adverse outcomes, healthcare resource utilization and costs for complicated UTIs (cUTIs) compared to standard urine culture.

  • UTI
Back To Top